<DOC>
	<DOCNO>NCT00204516</DOCNO>
	<brief_summary>The purpose vaccination protocol induce specific immune response melanoma associate antigen intradermal injection mRNA cod correspond antigen .</brief_summary>
	<brief_title>Vaccination With Tumor mRNA Metastatic Melanoma - Fixed Combination Versus Individual Selection Targeted Antigens</brief_title>
	<detailed_description>vaccination protocol induce clinically specific immune response melanoma associate antigen intradermal injection mRNA cod correspond antigen . Half patient treat mRNA cod Melan-A , Mage-A1 , Mage-A3 , Survivin , GP100 Tyrosinase . The half patient treat individualized selection mRNAs analysis overexpressed melanoma antigen autologous tumor tissue . GM-CSF use adjuvant . Phase I/II clinical trial analyse safety immune response stage III/IV melanoma patient .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>malignant melanoma stage III/IV fresh frozen tumor tissue available informed consent give Karnofsky &gt; = 70 % brain metastasis parallel chemotherapy systemic treatment glucocorticoid malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>vaccination</keyword>
	<keyword>mRNA</keyword>
</DOC>